If you are not happy with the results below please do another search
Epygenix Therapeutics, Inc. is developing precision medicine for rare and catastrophic forms of genetic epilepsy, such as Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, and Otahara syndrome.
How To Find Us
140 E. Ridgewood Ave.
Suite 415, South Tower
Paramus, NJ 07652
Phone: 1 (201) 940-7377
Fax: 1 (201) 940-7218
- Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100
- Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100
- EpyGenix Launches Phase II Trial for EPX-100
- Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies